• About
  • Companies
  • Technology & AI
  • Who We Serve
  • Investors
  • Contact

Wellgistics Health to Announce First Quarter 2026 Financials on Tuesday May 19, 2026

TAMPA, FL / ACCESS Newswire / May 15, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) (“Wellgistics” or the “Company”), a leading healthcare technology and pharmaceutical distribution company, today announced that it will report financial results...

Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program

Highlights:WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutionsCombination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its...

Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services

Highlights:According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based...

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operationsIntegrated platform accelerates pharmaceutical access, fulfillment, and commercializationCombined ecosystem provides potential reach to an estimated 200,000+ patient lives across...

Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders

TAMPA, FL / ACCESS Newswire / March 23, 2026 / Wellgistics Health, Inc. (“Wellgistics” or the “Company”) (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent (“LOI”) to evaluate a...
« Older Entries
Next Entries »

Recent Posts

  • DataMEDS AI Unveils New Corporate Website
  • DataMeds AI Litigation Settlement Extinguishes ~$19 million In Liabilities and Retires 364,099 Common Sharessked
  • DataMEDS, AI. Acquires Helomics AI Cancer Diagnostics Lab and Precision Oncology CRO Businesses from Axe Compute
  • Datameds, AI., and Tollo Health Partner with the NFL Alumni Association for Health Lives Here National Campaign Rollout
  • CORRECTION FROM SOURCE: DataMeds AI and Tollo Health Announce Fall 2026 Cold & Flu #Back2School50% Marketing Campaign for Viral Infections Medical Food Galectovid™

Recent Comments

No comments to show.

© 2026 DataMEDS AI. All Rights Reserved.

  • Follow
  • Follow